Mylan settles over Brovana; launches generic Boniva in UK and Italy

US generic drugs major Mylan (Nasdaq: MYL) has entered into an agreement with Sunovion Pharmaceuticals, a unit of Japanese drugmaker Dainippon Sumitomo Pharma to resolve the parties' patent litigation relating to Sunovion's Brovana (arformoterol), a lung disorder treatment.

The US District Court for the Southern District of New York's Final Judgment and Order notes that the parties have entered into a settlement and license agreement and that Sunovion has acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana product. These patents expire on June 22, 2021. The terms of the parties' agreement are confidential.

Mylan chief executive Heather Bresch commented, "We are pleased with this settlement and remain confident in the intellectual property protecting Perforomist, as well as our combination product for the treatment of chronic obstructive pulmonary disease (COPD), currently in development. We believe this settlement and judgment by the Court further strengthen the potential of our Specialty franchise and its portfolio of products." Mylan intends to appeal the judgment concerning other Mylan patents that were litigated.